Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. You know, hypertension and chronic kidney ...

Study findings could have implications for implementing targeted evidence-based therapies to slow CKD progression. PHILADELPHIA—Undiagnosed early chronic kidney disease (CKD) is highly prevalent among ...

PHILADELPHIA—The proportion of patients with type 2 diabetes who have uncontrolled hypertension is higher in patients with chronic kidney disease (CKD) than those without CKD, investigators announced ...

Please provide your email address to receive an email when new articles are posted on . Patients on the clinical decision support system had greater systolic blood pressure change. Mean systolic blood ...

Despite the fact that albuminuria represents a key risk factor for chronic kidney disease (CKD), even in the absence of reduced filtration, testing for the condition is low among adult patients with ...

Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial ...

A computerized clinical decision support (CDS) tool for primary care helped lower blood pressure (BP) in patients with chronic kidney disease (CKD) and uncontrolled hypertension, a cluster-randomized ...

Childhood cancer survivors had an increased risk of chronic kidney disease and hypertension. Childhood cancer survivors had twofold and fourfold higher adjusted risks versus a hospitalized cohort and ...

For patients with type 1 diabetes (T1D), a positive test or hospitalization for COVID-19 increases the risk of developing hypertension, chronic kidney disease (CKD), and diabetic ketoacidosis (DKA).

Mineralys Therapeutics is investing heavily in R&D for its lead candidate, lorundrostat, a treatment for hypertension and chronic kidney disease. R&D expenses nearly doubled from Q1 2022 to Q1 2023.